Foreword  by Nord, Carl.Erik
Foreword
Antibiotic resistance has resulted in a continuous
need for new therapeutic alternatives. However,
we see very few new anti-infective drugs. The
reason for this is the increasing cost of develop-
ment; the economic return is so limited that some
pharmaceutical companies have decided to leave
the ﬁeld of infectious diseases. The ultimate threat
is that we may ﬁnd ourselves in a position where
patients cannot be treated because effective drugs
are not available.
The European Society of Clinical Microbiology
and Infectious Diseases believes that action must
be taken now, to address this problem. Accord-
ingly, a symposium entitled ‘Inﬂuence of the
regulatory environment on antimicrobial resist-
ance’ was organized at the 14th ECCMID in
Prague in May of this year, and a second
symposium entitled ‘Antimicrobial therapy in
the 21st century’ was held in Stockholm the
following month, a report of which was published
in the last edition of the ESCMID News (No. 3,
2004, http://www.escmid.org). A position paper
entitled ‘Lack of development of new antimicro-
bial drugs: a potential serious threat to public
health’ is currently in press.
This issue constitutes an important contribution
to the ongoing discussion of the current situation.
Carl.Erik Nord
Supplements Editor
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
